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Tumors are complex organs with a unique ecosystem containing tumor cells entangled with 
various infiltrating cells. Tumors have distinct signaling signatures, which confers upon it the 
ability to grow in the primary host organ and further disseminate to other parts of the body. 
Tumors are a heterogeneous mix of sub-clones raised through genetic evolution. Concurrently, 
strong evidence suggests that nongenetic variables such as developmental cues add to this 
functional heterogeneity within individual tumors. Interestingly, multiple pathways involved 
in human organ development are restored and upregulated in various adult cancer.  
p21-activated kinase 4 (PAK4) is a downstream effector of the Cdc42 and Rac1 small Rho 
family GTPases. PAK4 is involved in embryonic development, but its expression is also 
upregulated in different cancer types. Formerly, reverse genetic efforts to study PAK4 have 
been hampered due to the embryonic lethality under the complete depletion of PAK4. 
Consequently, multiple conditional Pak4 knockout murine models have been developed to 
study the possible role of PAK4 in various stages of tissue development.  
The overall aim of this thesis is to explore the role of PAK4 in breast and pancreas organ 
development and to dissect its role in the formation of pancreatic ductal adenocarcinoma 
(PDAC).  
In paper I, we dissected the role of PAK4 in mammary gland development. Conditional Pak4 
gene depletion in the murine mammary gland did not affect this organ’s normal physiology or 
development. Moreover, Pak4 depletion was dispensable for normal murine pancreas 
development and whole-body hemostasis maintenance paper II. Therefore, the mouse model 
developed in paper II was further crossed with the Pdx-Cre; K-rasG12D/+ model to investigate 
the role of Pak4 in PDAC formation in paper III.  
We demonstrate in paper III that Pak4 depletion significantly reduces the formation of pre-
neoplastic lesions via inhibition of KrasG12D-driven acinar to ductal reprogramming (ADR). 
The aforementioned halt is accompanied by increased senescence-like growth arrest and 
decreased apoptosis. 
Notably, PAK4 gene expression was higher in human PDAC tumors than the normal tissue, 
and its protein expression was elevated in human pancreatic intraepithelial neoplasia (PanIN) 
and PDAC compared with the normal tissues.   
In sum, this thesis improves our understanding of the role of PAK4 in organ development and 
provides insight into the possible role of PAK4 in PDAC initiation and progression. 
  
LIST OF SCIENTIFIC PAPERS 
 
 
I. Parisa Rabieifar, Ting Zhuang, Tânia Costa, Miao Zhao and Staffan 
Strömblad (2019). Normal mammary gland development after MMTV-Cre 
mediated conditional PAK4 gene depletion. Scientific Reports 9, 14436. 
https://doi.org/10.1038/s41598-019-50819-4  
*Parisa Rabieifar and Ting Zhuang contributed equally. 
 
II. Miao Zhao, Parisa Rabieifar, Tânia Costa, Ting Zhuang, Audrey Minden, 
Matthias Löhr, Rainer Heuchel and Staffan Strömblad (2017). Pdx1-Cre- 
driven conditional gene depletion suggests PAK4 as dispensable for mouse 
pancreas development. Scientific Reports 7, 7031. 
https://doi.org/10.1038/s41598-017-07322-5 
 
III. Parisa Rabieifar, Miao Zhao, Carlos. F. Moro, Tânia D.F. Costa, Bela 
Bozoky, Nicholas P Tobin, Matthias Löhr, Rainer Heuchel, Daniel Öhlund, 
Staffan Strömblad. PAK4 governs Kras-driven premalignant acinar cell 
reprogramming. Manuscript.   
 
 
Scientific paper not included in the thesis 
 
I. Tânia Costa, Ting Zhuang, Julie Lorent, Emilia Turco, Helene Olofsson, 
Miriam Masia-Balague, Miao Zhao, Parisa Rabieifar, Neil Robertson, Raoul 
Kuiper, Jonas Sjölund, Matthias Spiess, Pablo Hernández-Varas, Uta 
Rabenhorst, Pernilla Roswall, Ran Ma, Xiaowei Gong, Johan Hartman, 
Kristian Pietras, Peter D. Adams, Paola Defilippi and Staffan Strömblad 
(2019). PAK4 suppresses RELB to prevent senescence-like growth arrest in 






1 INTRODUCTION ......................................................................................................... 1 
 1.1 Organ development .................................................................................................. 1 
 1.2 The mammary gland  ............................................................................................... 1 
       1.2.1 Development, organisation, and function ....................................................... 1 
       1.2.2 Signaling pathways in mammary gland development ................................... 3 
       1.2.3 Different cell types of the mammary gland .................................................... 4 
 1.3 The pancreas ............................................................................................................ 6 
       1.3.1 Development, organisation, and function ....................................................... 6 
       1.3.2 Signaling pathways in pancreas development ................................................ 8 
 1.4 Cancer ................................................................................................................... 9 
      1.4.1 Hallmarks of cancer ....................................................................................... 10 
      1.4.2 Cellular senescence ........................................................................................ 10 
 1.5 Pancreatic cancer .................................................................................................... 11 
      1.5.1 Pancreatic cancer etiology ............................................................................. 11 
      1.5.2 PDAC- Pancreatic ductal adenocarcinoma ................................................... 11 
      1.5.3 PDAC initiation and acinar cell reprogramming ........................................... 12 
 1.6 p21-activated kinases (PAKs) ................................................................................ 13 
      1.6.1 p21-activated kinase 4 (PAK4) ...................................................................... 14 
      1.6.2 PAK4 in organ development and cancer ....................................................... 15 
2 RESEARCH AIMS ...................................................................................................... 17 
3 METHODOLOGICAL CONSIDERATIONS ........................................................... 19 
 3.1 Animal research ..................................................................................................... 19 
 3.2 Ethical consideration .............................................................................................. 21 
4 RESULTS AND DISCUSSIONS ............................................................................... 23 
5 CONCLUSION ............................................................................................................ 27 
6 POINTS OF PERSPECTIVE ...................................................................................... 29 
7 POPULAR SUMMARY OF THE THESIS ............................................................... 31 
8 ACKNOWLEDGEMENTS ........................................................................................ 35 
9 REFERENCES ............................................................................................................ 39 
 
  































Acinar cell reprogramming 
Acinar to ductal metaplasia 
Autoinhibitory domain 
Aldehyde dehydrogenase 
Carbohydrate antigen 19-9 
Carbohydrate antigen 125 
Centroacinar cells  
Carcinoembryonic antigen 
Cytokeratin 19 
Embryonic day  
Extracellular matrix 
Epithelial-mesenchymal transition 
Embryonic stem cell 
G protein-coupled receptor 
Genetically engineered mouse model  
Glucose tolerance test 
Intraductal papillary mucinous neoplasm 
Insulin tolerance test 
PDX1-Cre/Lox-Stop-Lox (LSL)-KrasG12D 




Mouse mammary virus long terminal repeat 
Multipotent progenitor cells 
Metallothionein 
p21-activated kinases 
p21-activated kinase 4 












Pancreatic ductal adenocarcinoma 
Patient-derived xenograft  
Pancreatic and duodenum homeobox protein 1 













Pancreas associated transcription factor 1a 
Parathyroid hormone-related protein 
Senescence-associated beta-galactosidase 
Senescent associated heterochromatin foci 
Senescence-associated secretory phenotype 
Sonic hedgehog 
SYR-Box transcription Factor 9 





Terminal duct lobular units 
Terminal end buds 




Whey acidic protein  







1.1 Organ development 
Cells are the smallest structural units of living organisms (1). During development, distinct 
stem cells undergo a differentiation hierarchy and evolve to become progenitor cells, and 
ultimately differentiate into various cell types in a series of cell divisions (2-4). Under the 
influence of internal and external signaling, differentiated cells undergo continuous 
proliferation and migration that govern the subsequent tissue and organ development (5-7).  
1.2 The mammary gland 
1.2.1 Development, organization, and function 
Feeding the newborn with nutritious milk secreted from a cutaneous gland (i.e., mammary 
gland) is the unique aspect of mammalian physiology, which caused the naming of the class 
Mammalia by Carl Linnaeus (8). Despite the diverse anatomical characteristics by which 
mammals can be identified, lactation is considered the dominant character, reflecting its 
importance during early stages of mammalian development (9).   
Mammary glands are epidermal, exocrine glands that evolved more than 300 million years ago 
from apocrine sweat glands, and their primary function is lactation (10, 11). Upon birth, 
mammary gland represent an embryonic rudiment of the gland, which undergoes extensive 
expansion during puberty in response to hormonal changes. Throughout the female lifetime, 
the mammary gland encounters tremendous structural and functional changes induced by the 
menstrual cycle, pregnancy, lactation, and involution (12). Mice have five pairs of mammary 
glands located within the mammary fat pads, while in humans, there is only one pair of 
mammary glands enclosed in breasts (13). Mammary gland development consists of three 
distinct stages: embryonic, pubertal, and reproductive. 
Embryonic mammary gland development 
In mice, mammary gland embryonic development take place between embryonic day (E) 10.5 
and E18.5 (14, 15). Between day E10 and E11, the ectoderm enlarges to form the milk line 
extended from anterior to posterior limbs. At E11.5, five pairs of ectodermal placodes emerge 
along the milk line, rising slightly above the ectoderm (14, 16). Around E12.5, the placode 
sinks into the dermis and forms buds surrounded by mammary mesenchymal cells (17). 
Between E15.5 and E16, each bud proliferates and gives rise to sprouts that invade the 
mammary fat precursor (18). In female, the sprouts will eventually form a lumen that 
invaginates the epidermis and shape the nipple [Figure 1]. A significant difference between 
the mouse mammary gland and human breast at birth is that in mice, the rudimentary gland is 
formed from a single network of mammary branches, originated from the nipple, while in 
humans, several little ductal trees are joined at the nipple (19). Moreover, in male mouse 
embryos, activation of androgen receptors between E13.5 and E15.5 triggers mammary bud 
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degradation (20). This is in contrast to human mammary gland embryonic development, in 
which both male and female glands develop similarly during embryogenesis (19). 
 
Figure 1: Schematic summary of embryonic mammary gland development.  
Five pairs of mammary placodes are visible at E11.5. Placodes later invaginate to the dermis below 
them and form mammary buds which are in proximity to the mammary mesenchyme. Between E15 and 
E18.5, each bud proliferates, and form sprouts that eventually give rise to primary embryonic mammary 
branches. MB: mammary bud.  
From: (17)- Copyright: Permission from Professor  Christine J. Watson 
Pubertal mammary gland development 
The mammary gland remains unchanged from birth to puberty (21). During puberty, hormonal 
release from the pituitary gland and ovaries orchestrates the formation of terminal end buds 
(TEBs), a spherical structure that encapsulates the tip of the primary ducts. Upon estrogen (E) 
exposure, TEBs generate additional primary ducts, leading to expansion of lateral secondary 
branching [Figure 2.A] (22). Ductal growth further continues until the mammary tree reaches 
the end of the mammary fat pad (5 weeks in mice and 18-24 years in humans) (23, 24). Once 
the mammary gland reaches its maximum length, TEBs stop proliferating and shrink in size 
(25). The final tree-like structure consists of luminal epithelial cells, which are surrounded by 
contractile myoepithelium. The epithelium proliferates and diminishes during each menstrual 
cycle (26). In mice, the fully developed mammary gland is filled with adipocytes, while in 
humans, the mammary stroma is enriched in fibrous connective tissue (27).  
Reproductive mammary gland development 
A crucial difference between mouse and human mammary glands is the timing of the lobular 
unit formation. In the human terminal duct lobular units (TDLUs) are already formed during 
puberty, whereas, in mice, the formation of lobuloalveolar structures only appears at the onset 
of the pregnancy and exposure to an excess of progesterone (28, 29). In the late stages of 
pregnancy and lactation, and under the influence of prolactin, luminal epithelial cells produce 
milk and secret it into the alveoli of the lumen. Further, the suckling of the nipple by the 
newborn stimulates oxytocin secretion. In response to oxytocin surrounding myoepithelium 




weaning and lack of milk suckling of the newborn, the ductal structure goes through apoptosis 
and shrinkage to regains its inherent size in an involution event (30).  
1.2.2. Signaling pathways in mammary gland development 
The embryonic development of the mammary gland depends on the corresponding signaling 
between epithelium and the mesenchyme, which is regulated by a myriad of factors, e.g., 
estrogen, androgen, transcription factors, growth factors, extracellular matrix (ECM) 
components, as well as epithelial-mesenchymal signaling through parathyroid hormone-related 
peptide (PTHrP) (31-34).  
In the mouse embryo, the early embryonic placodes are surrounded by a layer of primary 
mesenchymal cells that regulates cell proliferation and invasion of the bud’s tip that eventually 
leads to the formation of primary sprouts (35). Continued signaling from primary mesenchymal 
cells contributes to the formation of a ductal tree at birth. After birth, matrix metalloproteinases 
(MMP) induce ECM remodeling during lateral branching of the mammary gland and facilitate 
further expansion of the mammary tree (36, 37).   
Once pregnancy occurs, progesterone (Pg) and prolactin (Prl) induce extensive side-branching, 
differentiation, and formation of the lobuloalveolar structure required for milk secretion during 
lactation [Figure 2.A] (38-41). When the lobuloalveolar structure is developed, further 
development of secretory mammary epithelium is dependent on prolactin receptor (PrlR) and 
downstream signaling, where signal transducer and activator of transcription5 (Stat5) secure 
epithelial proliferation and differentiation of mammary alveoli during pregnancy (38, 42).  
Upon weaning of the newborn, excess milk leaks to the mammary epithelium, initiating the 
involution process in which mammary epithelial cells regain their initial mammary duct 
features (11). Involution occurs in two phases: an initial reversible phase which is induced by 
local cues and occurs 48 hours after weaning and is characterized by massive apoptosis, 
alveolar cell detachment, and discharging of cells into the lumen (43-45). The STAT (Signal 
transducer and activator of transcription) family of proteins plays a crucial role during this first 
phase of involution, where STAT5A and STAT5B positively regulate survival signals through 
the PI3Ks (Phosphoinositide 3-kinases) pathway, while STAT3 acts as a negative regulator 
(46, 47). The second phase is irreversible and is regulated by secreted factors such as serine 
proteases and MMPs. The expression of these factors initiates during the first phase of 
involution; however, they remain to be activated until the beginning of the second phase. 
Following MMPs and proteases’ activation, basal membrane remodels and alveoli collapse, 




Figure 2: Schematic summary of postnatal mammary gland development in the mouse.  
 
A: Mammary gland remains dormant until puberty. At the onset of puberty and under the influence of 
estrogen, ductal morphogenesis occurs. Progesterone further regulates the side branching. Once 
pregnancy occurs, estrogen, progesterone, and prolactin contribute to alveolar expansion. Prolactin is 
the main regulator of the late stage of pregnancy and lactation. E: Estrogen, Pg: Progestrone, Prl: 
Prolactin.  
B: Structure of terminal end bud during puberty.  
 
From: (50). Copyright © 2020, The American Physiological Society  
 
1.2.3 Different cell types of the mammary gland 
Epithelial cells 
The mature mammary gland is compromises of apical, luminal epithelial cells expressing 
Keratin 8 and 18, and myoepithelial cells in contact with basal membrane cells and express 
Keratin 5, 14, and smooth muscle actin (51-55). There are multiple epithelial cells in TEBs 
such as: (Cap) epithelial cells that appear at the end of TEBs and are in contact with the stroma 
through a thin basal lamina, the body cells that are in the interior part of the end buds, and the 




Adipocytes cover a large portion of the mammary gland, contributing to epithelial growth, 
angiogenesis, and communicate with other cell types within the gland (56, 57). During 
pregnancy and lactation, adipocyte volume is reduced, suggesting a role in milk production 
(56, 58).  
Fibroblasts 
Fibroblasts regulate communication with the epithelium during ductal branching and 
orchestrate the mammary gland morphogenesis via regulation of the ECM composition. 
Moreover, fibroblasts contribute to the synthesis of various growth factors and MMPs, which 
degrades the ECM and releases the growth factors embedded within the ECM (59-61).   
Vascular cells 
During puberty, the lymphatic and vascular networks develop in proximity to the mammary 
epithelial tree to facilitate carrying nutrients and fluids into milk (62, 63).  
Immune cells 
Macrophages and eosinophils are required to regulate the invasion of branching tips through 
the mammary fat pad. They also regulate epithelial cell death and adipocyte reconstitution 





1.3. The pancreas  
1.3.1. Development, organization, and function 
The pancreas is an organ located in the stomach’s abdominal cavity. It is about 12-25 cm in 
length and has 70 to 150 grams of weight in human. The head of the pancreas is connected to 
the duodenum, where the main pancreatic ducts are attached to the bile duct, and its narrow tail 
extends to the left side of the body very close to the spleen. The pancreas consists of two 
glandular structures: the exocrine pancreas, which contributes to food digestion by releasing 
enzymes into the duodenum, and the endocrine pancreas that maintains blood glucose level 
[Figure 3] (66-68).  
Exocrine pancreas 
The exocrine pancreas compartment makes up 95% of the organ, consisting of acinar, 
centroacinar, and ductal cells, and in mice, it develops at ~E11.5-12.5 (66, 69).  
Adult acini are pyramid-shaped exocrine cells that contain a pronounced amount of 
endoplasmic reticulum and a massive number of secretory granules containing digestive 
enzymes that are secreted into the duodenum via the pancreatic duct [Figure 3]. The 
specification of acini is determined by pancreas-associated transcription factor 1a (Ptf1a) (70). 
During differentiation, acinar cells express Rbpjl and Mist1; the consequent mature acini 
express Ptf1a, Gata4, Mist1 (Bhlha15), and Nr5a2 (71, 72). Pancreatic acini are connected to 
the small pancreatic ducts via centroacinar cells (CACs) (73). CACs are derived from 
multipotent progenitor cells (MPCs), and they keep expressing some of the progenitor markers 
such as Ptf1a, Pdx1, Nkx6.1, and Sox9 throughout the development (74-76). CACs maintain 
their progenitor-like feature in the adult pancreas, with sustained Notch signaling that secures 
their identity (77).  
 
  
Figure 3: Schematic representation of the 
pancreas.  
The pancreas consists of exocrine and 
endocrine compartments. Pancreatic acinar 
cells locate around a central lumen which 
opens to the ducts. Endocrine pancreases 
consist of Islets of Langerhans (pancreatic 
islets), formed in proximity with pancreatic 
ducts. 
 






Endocrine pancreas  
The endocrine gland is formed by cell clusters called “islets of the Langerhans” or “pancreatic 
islets,” which make up 1-2% of the organ’s weight (66). Pancreatic islets contain five different 
cell types that produce endocrine hormones: 1) α-cells producing glucagon, 2) β-cells 
producing insulin and amylin, 3) γ-cells producing pancreatic polypeptide(pp) 4) δ-cells 
producing somatostatin, and 5) ε-cells producing ghrelin. These endocrine hormones work 
together to secure a balanced blood glucose level. Where insulin decreases the blood sugar 
level, glucagon increases it, and somatostatin regulates both insulin and glucagon’s secretion. 
The islet structure is quite similar among mammals; however, there is a difference between 
human and rodent islets. Rodent islets are made of β-cells in the middle surrounded by 
peripheral α-cells while human islets are formed of interconnected α and β-cells [Figure 4] 
(79, 80).   
Both the exocrine and endocrine pancreas are primarily composed of epithelial cells. 
Nevertheless, endocrine islet forming cells lose their epithelial connectivity with the lumen and 
tight junctions later during the development and create cord-like structures with proximity 
along the duct and blood vessels. Within the islets, positive glucagon cells appear at E9, while 
insulin-containing granules are not seen until the subsequent transition periods (81). After 
formation, β-cells slowly lose their contact with the mesenchymal layer, mainly supported by 
ECM molecules in the basement membrane such as fibronectin, laminin-1, collagen IV, and 
integrin. The location of endocrine cells and their appearance are dependent on close 











Figure 4: Schematic representation of islets of the pancreas in humans and mice. 
While primate islets formed from a random distribution of cells, rodent islets have a uniform 
architecture with α and δ cells located on the periphery of the islets and β-cells in the center.  
 






1.3.2. Signaling pathways in pancreas development 
Early pancreas development signaling  
Signaling involved in early pancreas development is derived from the notochord, and the 
surrounding mesenchyme. Before the start of the pancreatic budding, dorsal notochord releases 
morphogenic signaling such as activin bB and FGF2 to suppress sonic hedgehog (Shh) 
signaling and allowing pancreatic gene expression and organogenesis (83). Soon after, 
mesenchymes release FGF10, BMPs, and follistatin which in turns activate pancreatic and 
duodenal homeobox 1 (Pdx1) at E8.5, followed by pancreas-specific transcription factor 1a 
(Ptf1a) at E9.5 (84-86). From E9.5 to E12.5, Notch signaling oversees maintaining multipotent 
progenitor cells (MPCs) pool, MPCs, in turn, co-express Ptf1a, Sox9, and Pdx1 and eventually 
gives rise to all types of pancreatic cells (87-93).   
Early pancreas morphogenesis signaling 
The transition of the MPCs to the complete organ is a two-step process (94). The primary step 
starts at E12.5 and contains the segregation of tip and trunk domains. It is regulated by the 
Notch pathway and crosstalk between mesenchyme and endothelium (95-97). In which tip cells 
are identified by expression of Cpa, c-Myc, and Ptf1a, and the trunk domain is identified by 
expression of Onecut-1, Tcf2, Hes1, Prox1, and Sox9 (74-76, 98-102). In the second phase of 
transition, tip cells give rise to acinar cells under the influence of Ptf1a, Rbp-jl, and 
Nr5a2/LRH-1, while trunk cells are bipotential and form both endocrine and ductal cells. A 
fraction of cells in the trunk domain express transcription factor Ngn3 and transform to 
endocrine cells (102-104). However, the subset of cells which do not activate Ngn3 gain a 
ductal cell phenotype and become ductal cells via expression of Sox9, Tcf2, Onecut1, Hes1, 
Prox1, and Glis3 [Figure 5] (101, 105-111).   
Mature endocrine and exocrine development signaling 
Wnt/b-catenin signaling pathway is the master regulator of acinar cell development by 
maintaining the MPCs pool (112). Furthermore, follistatin secreted from mesenchyme 
contributes to acinar cell differentiation (113, 114). Like exocrine, endocrine development is 
depending on the Wnt/b-catenin signaling pathway, which regulates β-cell number and ensures 







Figure 5: Early pancreas morphogenesis.  
The mature pancreas is formed from pancreatic progenitor cells. Within the first phase of transition, 
progenitor cells maintain pancreatic cell’s identity. During the second transition phase, progenitor 
cells obtain either tip or trunk identity. While tip cells further develop to acinar cells, trunk cells 
undergo further signaling to become either endocrine or ductal cells.  
From: (116). Copy right © 2011, American Diabetes Association 2011 
 
1.4 Cancer 
Cancer existed long before human existence. Paleopathological findings indicate evidence of 
tumors in animals in prehistoric times. The earliest evidence of cancer in a human was first 
introduced by Edwin Smith Papyrus, dated approximately 3000 BC. The terms Carcinoma 
(malignant tumor) and Cancer (ulcerated malignant tumor) were first introduced by 
Hippocrates (460-375 BC). The word Onco (swelling) was later introduced by Greek physician 
Galen 130-200 AD (117).  
Cancer is not just one disease but a large group of disorders, characterized by their unregulated 
cell growth, uncontrolled cell division, and ability to spread to other parts of the body. There 
are more than 200 known cancer types, of which approximately 70% are derived from epithelial 
cells (118, 119). Cancer is characterized by defective cells that are not following the “normal” 
rules of tissue hemostasis. The steps leading to the transformation of normal cells to become 
cancer cells and subsequent spread of cancer cells to metastatic regions are well described in 








1.4.1 Hallmarks of cancer 
As normal cells lose their inherent features and acquire a neoplastic state, they obtain a series 
of traits that enables them to become tumorigenic and eventually develop the ability to spread 
to other organs. In 2000, Douglas Hanahan and Robert Weinberg described the six crucial 
“core” traits that facilitate cancer growth and their subsequent spread to the metastatic region, 
including 1) avoiding growth suppressors, 2) sustained proliferative signaling, 3) resistance to 
cell death, 4) enabling replicative immortality, 5) activating invasion and metastasis, and 6) 
inducing angiogenesis. A decade later, the authors updated the list of hallmarks by adding four 
new identifying traits. Two “emerging hallmarks”, 7) evading immune response, and 8) 
interfering with cellular energetics, and two “consequential hallmarks”, which facilitate the 
gaining of both “core” and “emerging hallmarks”: 9) genome instability and 10) tumor-
promoting inflammation (120, 122).  
1.4.2 Cellular Senescence  
Aging is a common characteristic of multicellular organisms and is defined by the inability to 
maintain the function of multiple cells or a particular tissue. Aging often accompanies both loss 
of function alterations, like what is seen in age-related degenerative diseases, and gain-of-
function changes that allow the cells to propagate indefinitely, such as cancer.  
Cancer is an age-related, gain-of-function disease in which cells acquire the ability to 
proliferate, migrate and colonize to an ectopic site via bypassing different hallmarks of cancer 
(123). Both hyperplastic and degenerative aging diseases commonly go through a stress 
response named “cellular senescence”, which imposes a proliferation arrest on damaged cells 
and facilitates tissue hemostasis maintenance (124).  
Cellular senescence occurs in response to myriads of stimuli such as DNA damage, telomere 
shortening, mitogens, proliferation-associated signals, mitochondrial dysfunction, epigenomic 
damage, and tumor suppressor activation (123). It was initially believed that senescence is 
essentially a permanent-growth arrest. However, recent studies indicate that, senescent cells 
can acquire a certain degree of stemness upon chemotherapy that helps them escape from cell-
cycle blockade (125).  
There is no universal marker to detect senescence cells; instead, senescent cells are defined by 
several characteristics (126). Senescent cells are characterized by being larger and more 
flattened than healthy cells and can be detected by the presence of senescence-associated-b-
galactosidase (SA-b-gal), a marker of lysosomal degradation (127, 128). Other markers of 
senescent cells are senescence-associated secretory phenotype (SASP), presence of telomere 
dysfunction- induced foci (TIF), senescent associated heterochromatin foci (SAHF), increased 





1.5 Pancreatic cancer 
1.5.1 Pancreatic cancer etiology  
Pancreatic cancer is the 7th leading cause of cancer death, causing around 4% of all cancer 
deaths with only 9%, 5-years survival rate, and a median survival of <11 months (132-134). 
The term pancreatic cancer refers to tumors rising from exocrine, endocrine, and ductal cells. 
However, more than 90% of the pancreatic neoplasms have ductal differentiation (135). The 
remaining 10% are “non-ductal” tumors, including pancreatic endocrine neoplasm (PEN), 
pancretoblastoma, and solid-pseudopapillary neoplasm (136).  
Many risk factors contribute to pancreatic cancer occurrences, such as smoking, family history 
of the disease, chronic pancreatitis, obesity, helicobacter infection, and periodontal disease 
(137-142). Seven to 10% of all pancreatic cancer cases are attributed to inherited mutations 
such as mutations in tumor suppressor STK11, BRCA1 or BRCA2, germline mutation in 
CDKN2A, and DNA repair genes (i.e., MLH1, MSH2, MSH6, and PALB2) (143-146).  
Pancreatic cancers’ dismal prognosis is often attributed to its difficulty to be diagnosed, mainly 
due to its very mild, if any, symptoms before it develops to advanced stages. Unfortunately, 
the symptoms present at the time of diagnosis are often attributed to benign conditions and 
delayed diagnosis. Some of the commonly reported symptoms include abdominal pain, 
jaundice, new-onset diabetes, nausea, weight loss, and back pain (147, 148).  The routine 
diagnostic techniques are multidetector CT angiography and MRI.  Carbohydrate antigen 19-9 
(CA19-9), carcinoembryonic antigen (CEA), and CA125 are used as serum biomarkers for 
pancreatic cancer diagnosis, with CA19-9 having the highest specificity of 82% for diagnosis 
in symptomatic patients (149). 
 1.5.2 Pancreatic ductal adenocarcinoma (PDAC) 
PDAC has a bleak prognosis, with only 9% 5-year survival after diagnosis (132). The early 
stage of pancreatic cancer is usually asymptomatic, mainly due to the location of the tissue. 
Therefore, approximately 80% of PDAC patients are already at an advanced or metastatic stage 
at the time of diagnosis and therefore not eligible for undergoing surgery (150). The majority 
of PDAC tumors arise from the pancreas head and are often diagnosed earlier due to biliary 
obstruction (151). However, tumors in the pancreas body and tail are diagnosed later and have 
already spread to distant organs at diagnosis. Hence, PDAC in these locations is associated 
with a poorer prognosis (152). The most common symptoms are abdominal pain, jaundice, and 
weight loss (153). To better categorize and allocate therapy regimens for PDAC, multiple large-
scale DNA sequencing and gene expression profiling have been performed in recent years. 
Two molecular subtypes have been identified: 1) “classical/canonical subtype” characterized 
by epithelial-like gene expression, and 2) “quasi-mesenchymal/basal-like subtype” carrying a 
worse prognosis than the classical subtype (154-156).  
PDAC is an intractable disease due to its tumor heterogeneity and multiple cellular events that 
contribute to the formation of the disease. PDAC tumor heterogeneity in the same tumor and 
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among different patients makes it challenging to implement targeted therapies available for 
other cancer types, such as against EGFR in lung cancer or BRAF in melanoma (157-159).  
Moreover, multiple signaling pathways such as Kras, CDKN2A/p16, TP53, and SMAD4 are 
altered during the progression of PDAC, contributing to multiple resistance mechanisms 
developed during PDAC treatment (160). Finally, the dense desmoplastic PDAC tumor 
microenvironment (TME) is characterized by decreased vasculature, altered immune cell 
filtration, and hypoxia that facilitates tumor growth and eliminates drug delivery (161). To date, 
surgery is the primary treatment of pancreatic cancer followed by adjuvant therapy with 
gemcitabine, capecitabine, and mFOLFRINOX after completing surgical resection (162). 
However, these treatments are not sufficient for patients with late-stage disease (163).  
1.5.3 PDAC initiation and acinar cell reprogramming 
PDAC can rise from three different precursor lesions, intraductal papillary mucinous neoplasm 
(IPMN), pancreatic intraepithelial neoplasia (PanIN), and mucinous cystic neoplasm (MCN) 
(164). Most PDAC lesions originate from PanIN and less prevalently from IPMN and in some 
rare cases from MCN. It was believed that PanINs originate from the ductal cells, primarily 
due to morphological resemblance and expression of the ductal marker like cytokeratin 19 
(CK19) (165-167). However, we now know that the most of the PanIN lesions originate from 
acinar cells (94, 165, 166, 168). Once acinar cells are insulted by acute damage, they lose their 
original phenotype and enter an intermediate, dedifferentiated duct-like metaplastic state, 
termed acinar to ductal reprogramming (ADR) [Figure 6] (169). Often, ADR is a transitionary 
state that is reverted once the acute damage is resolved. However, upon constant insult by 
oncogene activation or chronic pancreatitis, acinar cells lose their identity and acquire duct-
like features. Such trans-differentiation is called acinar to ductal metaplasia (ADM) (170-174).  
During ADM, acinar cells lose their capacity to express acinar genes such as Mist1, CPa1, 
elastase, and amylase and instead express ductal cell genes such as cytokeratin 19 (CK19), 
mucin1 (Muc1), Pdx, and Sox9 (68, 175). Both chronic pancreatitis and oncogenic Kras can 
initiate ADM. However, their presence alone is inadequate to further drive carcinogenesis 
beyond the premalignant PanIN stage to high-grade dysplasia and PDAC. Additional gene 
mutations, inflammation, and wild-type Kras activation are other subsequent mechanisms that 








Figure 6: Acinar plasticity and PDAC development 
Upon contact-mediated signaling, pancreatic injury, and oncogenic Kras activity, acinar cells undergo 
reversible trans-differentiation termed as acinar to ductal metaplasia (ADM), in which they lose their 
identity markers and obtain ductal fate markers. ADM becomes irreversible in the presence of gain of 
function Kras mutation. 
From: (182). Copyright © 2017, Nature Publishing Group, a division of Macmillan Publishers 
Limited.  
1.6. p21-activated kinases (PAKs) 
The p21-activated kinases (PAKs) are serine/threonine kinases and were primarily discovered 
as proteins that interacted with GTP-bound Rac (183).  PAKs act as downstream effectors of 
Cdc42 and Rac1 small GTPases (183, 184). The PAK family contains six members and is 
divided into two groups based on their sequence and structural homology (185). Group I of 
PAKs consists of PAK1, PAK2, and PAK3 and group II contains PAK4, PAK5 and PAK6 
(186). The protein structure of PAKs consists of a C-terminal serine/threonine kinase domain 
with a phosphorylation site and an N-terminal regulatory domain. The N-terminal regulatory 
domain is structurally different among the two groups. Group one PAKs are regulated with an 
auto-inhibitory mechanism, where two PAK monomers form a homodimer through the 
attachment of the auto-inhibitory domain (AID) of one molecule to the other PAK molecules 
kinase domain. Upon binding of activated small GTPases to the p-21 binding domain (PBD), 
the dimerization is terminated. This leads to phosphorylation of both molecules and initiation 
of their further kinase activity (187-189). Group II PAKs have a similar structure as group I 
but are missing AID, and therefore they were considered to be constitutively active (190). 
However, it has been shown that the PAK4 regulatory domain contains an AID-like 
pseudosubstrate sequence that inactivates its kinase activity (191, 192).   
PAKs control major cellular events such as cytoskeletal remodeling, DNA damage response, 
and mitotic progression. PAK family exerts their functions through their intrinsic kinase 
activity, their ability to shuttle between nucleus and cytoplasm, modulating the target gene 
expression, and employing their scaffolding activity. PAKs excessive expression is correlated 
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with growth signal self-sufficiency, cell proliferation, and invasion, cell survival, activating 
metastasis, and angiogenesis, all of which are hallmarks of cancer (122, 193, 194).  
PAK kinases have different expression patterns throughout development. Therefore, great 
efforts have been made to study their functions using knockout animal models. While Pak1and 
Pak3 knockout mouse models are viable and appear normal and fertile, Pak2 and Pak4 
knockout mice are embryonically lethal (195-198).  
Given PAKs’ involvement in diverse cell signaling and their fundamental role in cellular 
hemostasis, disruption in PAK signaling can disturb normal tissue functions and lead to 
different types of human disorders such as cardiac and neurological disorders and different 
types of cancer.  
1.6.1. p21-activated kinase 4 (PAK4) 
PAK4 is a group II PAK and is highly expressed during development and in many adult tissues 
(198, 199). Unlike group I PAKs, PAK4 lacks an autoinhibitory domain; instead, it contains 
an autoinhibitory-like pseudo-substrate sequence that inhibits its kinase activity (191). PAK4 
is involved in mediating multiple of cytoskeletal regulation such as the formation of filopodia, 
stress fibers disintegration, turnover of focal adhesion, as well as actin polymerization and de-
polymerization (200-202). Also, PAK4 regulates cell adhesion via interacting with avb5 
integrin and regulates adhesion dynamic [Figure 7] (200, 203, 204). Moreover, PAK4 
excessive expression is linked to prolonged cell survival, protection of cells from apoptosis, 
and bypassing of the oncogene-induced-senescence (OIS) barrier (196, 205, 206).  
Many of the cellular cues regulated by PAK4 are involved in tissue development and disturbed 
during cancer development; therefore, it is crucial to study the role of PAK4 in tissue 
development and cancer.  
                                                                                                                        Figure 7: PAK4 regulates 
different cellular functions 
and signaling pathways 
PAK4 mediates various 
cellular functions and 
signaling pathways 
including actin remodeling, 
pro-survival, anti-apoptotic 
pathways, and apical 
junction formation.  
From: (201). Copyright © 








1.6.2. PAK4 in tissue development and cancer 
 
PAK4 in tissue development 
Embryos subjected to Pak4 gene knockout die before E11.5 due to defects in the fetal heart, 
improper folding in neural tubes, and abnormalities in neuronal differentiation. Due to 
embryonic lethality upon total Pak4 knockout, conditional Pak4 gene knockout mice were 
developed to explore its function in development of various tissues. Although Pak4 gene 
knockout in the central nervous system and heart caused a malfunction in the normal tissue 
function, Pak4 conditional depletion in the mammary gland (paper I) and pancreas (paper II) 
did not alter either development or function of both organs (202, 207-210).  
PAK4 in cancer 
PAK4 is overexpressed in numerous cancer types such as endometrioid ovarian cancer, oral 
squamous cell carcinoma, and basal-like breast cancer (190, 211-218). In pancreatic cancer and 
ovarian cancer, PAK4 overexpression has been associated to PAK4 gene amplification (213, 
214, 219). Clinically, PAK4 overexpression correlates with a poor prognosis, more aggressive 
phenotype, and a higher chance of metastasis and distant tissue infiltration (220, 221).  
PAK4 promotes the transformation of normal cells to cancer cells via controlling the cell 
proliferation, survival, invasion, metastasis, and epithelial-mesenchymal transition (EMT) 
(222-225). Moreover, PAK4 exerts its function via interacting with diverse signaling pathways 
involved in cancer, such as the Wnt/b-catenin pathway, by phosphorylating and stabilizing b-
catenin in the nucleus and preventing b-catenin ubiquitination (226). Early studies suggest that 
PAK4 plays a central role in actin cytoskeletal reorganization by phosphorylation of LIMK1, 
which subsequently phosphorylates and inactivates cofilin, reducing the ability of cofilin to 
depolymerize F-actin (227, 228). PAK4 acts as an additional target in mutant K-ras-driven 
cancers such as pancreatic, colorectal, and lung cancers (229-231). In this thesis (paperIII) we 







2 RESEARCH AIMS 
Papers included in this thesis bring insight into the role of PAK4 in the development of 
mammary gland and pancreas, as well as in the formation of pancreatic ductal adenocarcinoma 
through the development and utilization of three novel transgenic mouse models. 
Paper I: To set up a transgenic mouse model with conditional Pak4 gene knockout in the 
mammary gland and determine the functional role of Pak4 in mammary gland development 
and its function.  
Paper II: To develop a novel transgenic mouse model with conditional Pak4 gene depletion 
in the mouse pancreas and further assess the role of Pak4 in pancreas development and its 
function. 









3 METHODOLOGICAL CONSIDERATIONS 
A detailed description of the methods used in this thesis is included in each constituent paper. 
In this section, I will discuss the main research tools that were used in this thesis.  
3.1. Animal research 
Mus Musculus (house mice) have been commonly used to set up in vivo animal models in 
human research. This is due to the physiological and genetic similarities between mouse and 
human and the relative ease of maintenance, breeding, and gene manipulation in the mouse 
(232, 233). Gene-targeted animal models have been a practical tool to study tissue development 
and diseases that can be mimicked in murine cells (234). Traditionally, to produce offspring 
with certain genetic traits that resembled cancer in human, animals were exposed to different 
stimuli which predisposed them to human conditions, such as UV radiation and DNA-
damaging chemicals (235).  
Today, usage of homologous recombination provides opportunities to manipulate mouse 
embryonic stem (ES) cells and produce either genetic knockouts or knock-ins mouse models 
(236, 237). A depletory genetic alteration is a powerful tool to inactivate a gene via disruption 
of its DNA sequence. However, if the modified gene is vital for embryonic development, 
conventional knockout genetic alterations will cause embryonic lethality. Therefore, a 
conditional genomic alteration was developed using the Cre-lox system, in which a mutation 
can be induced both spatially and temporally by crossing a mouse harboring a Lox gene with 
the one carrying the target gene (238, 239). Given the mosaic nature of the Cre gene depletion 
system, it is crucial to detect the gene depletion on the cellular level by using immunostaining 
or crossing with a reporter strain (240-242). 
PAK4 is required for embryogenesis; therefore, the Cre-lox knockout strategy has been used 
to generate different conditional Pak4 knockout mouse models (198, 207-209). This thesis 
contributes to PAK4 research by introducing three novels conditional Pak4 gene knockout 
mouse models. In paper I and II, we examined if Pak4 is essential for normal mammary gland 
and pancreas development. In paper III, we studied the role of Pak4 in a Kras-driven 
pancreatic ductal adenocarcinoma mouse model.   
Animal models of mammary gland development 
Different promoters have been used to conditionally overexpress or deplete genes from the 
mammary tissue using the Cre-lox system, such as mouse mammary virus long terminal repeat 
(MMTV-LTR), whey acidic protein (WAP), metallothionein (MT), and cytokeratin 14 (242, 
243). Among all aforementioned promoters, Cre recombinase under the control of MMTV-
LTR has been the most frequently used model to study mammary gland development due to 
its expression in epithelial cells and its activity during both non-lactating and lactating phases 
(244). MMTV-mediated Cre-expression is found in the mammary gland, seminal vesicles, 
harderian gland, and lymphoid cells (245, 246). Three mouse lines carrying MMTV-Cre 
transgene (lines A, D, and F) have been developed. It has been reported that while line D mice 
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can nurse their pups, both line A and F have impaired lactation, hence being unable to nurse 
their progeny. Therefore, it is crucial to choose the right Cre-mice line and include an MMTV-
Cre control group in studies exploring mammary gland function during lactation (247). In 
paper I, we took advantage of MMTV-Cre (lined D) mice to study Pak4’s role in the mammary 
gland development in the juvenile, adult, and lactation phases.  
Animal models of pancreas development 
Several animal models have been developed by taking advantage of different transcription 
factors involved in pancreas development and differentiation. Pdx1 and Ptf1a/p48 are 
expressed at the early stages of pancreas development and are two main transcription factors 
manipulated to study pancreas development both spatially and temporally. The homeobox gene 
Pdx1/IPF1 is expressed at E8.5-9 before the formation of buds, and its knocking out results in 
pancreas agenesis. Pdx1 expression is restricted to the pancreas, with a minor expression 
observed in the developing stomach and duodenum. Pdx-Cre expression controls the formation 
of all pancreas compartments (91). In paper II, Pdx-Cre promoter was used to explore the role 
of Pak4 in pancreas development. PAK4 expression was below the detection limit after 
analyzing the pancreas lysate obtained from Pak4 knockout mice, indicating Pdx-cre promoter 
expression was sufficient for successful Pak4 gene depletion in the pancreas. However, it is 
crucial to consider the Cre-mosaicism previously reported on the Pdx-1 promoter and be aware 
that a fraction of the pancreas epithelium will retain Pak4 expression (241).  
Animal models of Pancreatic ductal adenocarcinoma 
Different mouse models have been employed to recapitulate the formation of PDAC in vivo. 
While early efforts involved the expression of oncoproteins and viral vectors, more recent 
approaches involve the usage of the Cre-lox system to create mutant mice with pancreas-
specific oncogene activation (Kras) and/or inactivation of tumor suppressor genes (p53, 
p16INK4a, and Smad4) (248).   
Given that Kras mutations are observed in 90% of all pancreatic adenocarcinomas, this model 
has been commonly used in the field (229). The most widely used genetically engineered 
mouse models are either PDX1-Cre/Lox-Stop-Lox(LSL)-Kras, known as KC mice, or p48/LSL-
Kras (249). The benefit of using the aforementioned genetically engineered mouse models 
(GEMM) is that they both represent similar PDAC observed in humans by showing all stages 
of cancer progression from ADM and PanIN lesions to PDAC and finally metastasis to the 
liver, diaphragm, and pleural surfaces. Moreover, the fibroinflammatory reaction seen in both 
mouse models resembles those observed in human PDAC (94, 250). Given that both Pdx-Cre 
and p48-Cre mouse models mimic human PDAC and the availability of the Pdx-Cre mouse 
model in the lab (paperII), we used Pdx-Cre: LSL-KrasG12D to study the role of PAK4 in 
PDAC in vivo. To develop Pdx1-Cre; LSL-Kras G12D mice, a targeting vector with inhibitory 
effect on transcription and translation is flanked by LoxP sites. The Lox-Stop-Lox (LSL) 
construct is inserted in Kras locus upstream of locus1 that harbors G-A transition in codon 12 
(G12D). It is noteworthy considering that the model used in this study represents the mild 
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progression of PDAC in human; however, crossing these mice with lines harboring additional 
mutations occurring in tumor suppressor genes which are either inactivated or overexpressed 
in human PDAC such as INK4A, TP53, LKB1 or SMAD4 can speed up the progression of 
pancreatic lesions and give results to a full penetrance, metastasis, and formation of fully 
differentiated PDAC lesions as seen in human (251).  
Despite tremendous similarities between PDAC progression in KC mice with those of human, 
we should note their different etiology. Firstly, KC mice are a prenatal GEMM model; 
however, PDAC in humans is not a pediatric disease but somewhat likely to rise due to sparse 
mutation in adult pancreas. Secondly, PDAC patients have Kras mutation in a small subset of 
their cell types, and not all pancreatic compartments as observed in KC mice. Given the 
phenotype observed in paper III, in order to further understand the mechanisms by which 
PDAC rise from acinar cells, it is preferable to use the second generation PDAC GEMM mouse 
models in which a Kras oncogene is expressed only in the acinar cells (Elas-tTA; Tet-O-Cre; 
KRasLSL-G12Vgeo) and its expression can be controlled temporally with usage of doxycycline 
(167).    
Usage of animal models advanced our understanding of both human organ development and 
diseases remarkably; however, species-specific differences are often neglected among 
researchers. Lack of recapitulation of cancer events and different responsiveness to anti-tumor 
regimens are among the shortcomings of using mice as the model to recapitulate human cancer. 
In recent years, patient-derived xenograft (PDX) and tumor-derived organoids have been used 
as an alternative method to GEMMs as the pre-clinical tumor models of choice for anti-cancer 
drug screening (252).   
3.2. Ethical considerations 
Using animals in research has been highly debatable over the years. Animals used in research 
might suffer from discomfort throughout the experiment; therefore, scientists are asked to state 
both the rationale that the knowledge acquired outweigh the suffering imposed and a detailed 
procedure used in their research involving animal models (253). In Sweden, we secure the 
animal model well-being by obtaining an ethical permit issued by the regional ethical 
committee after a thorough evaluation of an ethical application. Procedures performed in this 
thesis have been performed following Swedish and European Union guidelines and were 
approved by Stockholm south animal ethics committee. The degree of difficulty of the 
experimental procedures performed in animals was moderate, and we always kept the 3Rs 
(Replacement, Reduction, Refinement) in mind when designing animal experiments. 
Using human tissue in research requires having informed consent before tissue collection. The 
informed concern should be under local and national regulations. Patient samples used in paper 
III of the thesis were obtained from PDAC cancer patients who underwent surgery. All the 
patients signed written informed consent. The study was performed according to the Helsinki 






4 RESULTS AND DISCUSSION 
Complete gene depletion of Pak4 in mice leads to embryonic lethality due to defects in the 
brain, heart, and vasculature (207-209). Therefore, it is crucial to investigate its role in different 
organ development.  In paper I and II, we explored the role of Pak4 in the mammary gland 
and pancreas development by developing two novel animal models with Pak4 conditional gene 
knockout in the corresponding tissue. In paper III, we crossed the pancreas mouse model 
developed in paper II with a KrasG12D mouse model and investigated the role of Pak4 in 
pancreatic cancer initiation and progression. In the following chapter, I will discuss the key 
findings obtained in each paper.  
Paper I: Normal mammary gland development upon Pak4 conditional knockout 
To deplete the Pak4 gene in the mammary gland, MMTV-Cre (line D) mice were crossed with 
Pak4-floxed mice (207, 208, 242, 254). The consequent Pak4 gene knockout (Pak4MEp-/-) and 
their control group (Pak4MEp+/+) mice were born at the expected Mendelian ratio. The female 
and male offspring were identically distributed, indicating that Pak4 genetic ablation does not 
affect the survival of either sex. We phenotypically compared the Pak4MEp-/- mice with their 
control group littermates. After performing immunolabelling, PAK4 expression was one-fourth 
in the mammary gland of the Pak4MEp-/- compared with those of Pak4MEp+/+. We further 
confirmed successful Pak4 depletion in luminal and myoepithelial cells of the mammary gland. 
Although a large portion of the ductal cells was negatively labeled for PAK4 in the Pak4MEp-/-
, there was still a noticeable fraction of the epithelium expressing PAK4, an indicator of 
incomplete Cre-penetration, as it was reported previously for MMTV-Cre-driven conditional 
gene depletion (242).  
Next, the morphology of ductal structures was examined using the whole-mount of inguinal 
mammary glands to compare Pak4MEp-/-   mice to their date-matched Pak4MEp+/+. We did not 
observe any defect in mammary duct morphogenesis upon Pak4 depletion in either mammary 
ductal elongation or branching in young (virgin week4) or mature (Virgin week 10) mammary 
glands.  
Knowing PAK4’s role in mediating both cell proliferation and invasion (201, 218, 255), we 
examined the cell proliferation status by immunofluorescent labeling of Ki67 and expression 
and activity of MMPs in the mammary gland tissue lysates from the virgin week 4 stage when 
the mammary gland is at the peak of branching. In line with our previous results, the lack of 
Pak4 did not change either cell proliferation or the expression of the examined MMPs in the 
Pak4MEp-/- group.  
Finally, we analyzed the ability of Pak4 gene knockout mothers to nurse their newborns, 
denoted by H&E staining and carmine-filled fat pad’s coverage at day 2 of lactation. We found 
that the mammary ducts completely covered the mammary fat pad, and the alveolar units of 
Pak4MEp-/- mice were fully developed. Moreover, the mothers lacking Pak4 in the mammary 
glands could nourish their pups sufficiently, indicated by equal pup body weight upon weaning.   
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Our results suggest that Pak4 inactivation in the mammary gland does not impair its 
development. Therefore, this model could be further used for testing Pak4’s role in mammary 
tumors and other diseases of the mammary gland.  
Lack of phenotypical dysfunction in the animal developed here prompted us to use this animal 
model to study the role of Pak4 in PyMT-driven mammary cancer (paper not included in this 
thesis) (216).  
Paper II: Normal pancreas development upon Pdx1-Cre mediated Pak4 gene depletion 
To study the role of Pak4 in pancreas development, we developed a conditional mouse model 
with Pak4 gene ablation in the pancreas epithelium by crossing Pdx1-cre mice with Pak4-
floxed mice (91, 207). Mice from Pak4 gene knockout and control groups were born at the 
expected Mendelian ratio, and Pak4 depletion did not affect any of the sexes survival. Cre-lox 
recombination and consequent Pak4 depletion in the knockout mice was confirmed by both 
genotyping for (Cre and lox) as well as immunoblotting for PAK4 in the whole pancreas lysate.  
Morphological quantification of the tissues obtained indicated no difference in the acinar, 
ductal, or islets of Langerhans distribution between the control and the knockout groups. 
Moreover, localization and ratio of different cell types within the exocrine and endocrine were 
not altered upon Pak4 depletion.  
Finally, Pak4 Knockout mice showed healthy body hemostasis by maintaining the same 
bodyweight as their control littermates; moreover, they could maintain their blood glucose level 
when challenged with a glucose tolerance test (GTT). This finding resembles those of Pak5 
and Pak6 depletion in the pancreas and suggests that each member of the group II PAKs is 
dispensable for pancreas development (256, 257). In contrast, depletion of Pak1 or Pak3 ablates 
the pancreas function to maintain whole-body glucose hemostasis (258, 259). This provides 
more evidence that different members of the PAK family have a distinct role in tissue 
development.  
However, the current study does not address the pancreas ability to maintain whole-body 
glucose hemostasis upon challenges such as high-fat diet or insulin tolerance test (ITT).    
Together, these data suggest that Pak4 gene depletion does not alter mouse pancreas 
development and function; therefore, this animal model could be a valuable tool for testing the 








Paper III: Pak4 gene ablation delays Kras-driven acinar cell reprogramming 
The PAK4 gene is frequently amplified in PDAC patient samples and overexpressed in 
pancreatic cancer cell lines (193, 219). By the knowledge acquired from Paper II, we took 
advantage of the animal model already in hand and crossed them with the established PDAC 
mouse model LSL; Kras G12D/+, which harbors the most common Kras mutation (G12D) and 
recapitulates all stages of the PDAC observed in human patients (229, 260).  
Pdx-Cre; Kras G12D; PAK4 fl/fl (knockout) were obtained by crossing Pdx1-Cre; PAK4 fl/fl mice 
with LSL; Kras G12D/+ and Pdx1-Cre; Kras G12D (control group) by crossing Pdx-Cre+/+ mice 
with LSL-Kras G12D/+. Upon examining the littermate, Pak4 knockout mice had a lower 
pancreas to body weight ratio than their control littermates, indicating less tumor burden in 
their pancreata upon Pak4 ablation.  
Acinar to ductal metaplasia (ADM) is the earliest anaplastic change observed in the Kras G12D 
model. Upon histological examination, we noticed that in the knockout mice, the area occupied 
by ADM was larger than controls. Moreover, the consequent metaplastic lesions formed were 
unable to further develop to neoplastic (PanIN) lesions, indicating an inability in the knockout 
mice to undergo complete acinar to ductal reprogramming. Consistently, both high-grade 
dysplasia and cancer lesion incidences were decreased in the Pak4 Knockout group. This 
suggests that Pak4 depletion hinders Kras-induced PDAC at the acinar to ductal 
reprogramming (ADR) stage. This finding concurs with the previous finding in patient PDAC 
samples stating that PAK4 expression peaks at early neoplastic lesions and remains high in 
advanced PDAC.  
Further progression of ADM towards cancer is challenged by a senescence-like growth arrest 
(261). Moreover, PAK4 appears to facilitate the bypass of cellular senescence escape in breast 
cancer (216). Together with the ADM halt observed in our model, these data tempted us to 
explore further the possibility that Pak4 inhibition may induce a senescence-like growth arrest 
in the ADM lesions, thereby delaying their further progression into PanIN lesions. Notably, 
Pak4 depletion blocked cell proliferation, increased expression of a common senescence 
marker (p16), and inhibited apoptosis in our mouse model.  
The observed ADM in our model is derived from a process called “de-differentiation,” in which 
mature acinar cells lose their identity and obtain more stem cell-like traits. In a healthy 
pancreas, this process often occurs in response to damage to the acinar cells. However, upon 
Kras mutation and/or inflammation, de-differentiated cells progress further to a metaplastic 
state and gain mature ductal cell features. The latter transition of becoming a ductal cell is 
called “trans-differentiation.” Once cells trans-differentiate, they gain the ability to further 
progress to a neoplastic state and eventually form PDAC. It has been previously reported that 
de-differentiation is accompanied by senescence induction and acquisition of stemness features 
(261). This, together with the finding that some de-differentiated cells in the Pak4 depleted 
pancreases neither re-differentiate nor trans-differentiate to a new cell type, may suggest that 
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PAK4 expression might push the senescent, de-differentiated cells to further progress to PanIN 
lesions (262).  
In summary, our findings establish PAK4 as a mediator of ADR during PDAC development, 





The results presented in this thesis demonstrate that PAK4 is dispensable for mouse mammary 
gland and pancreas development. Also, our finding establishes PAK4 as a promotor of Kras-
driven PDAC development.  
The two novel mouse models developed in the paper I and II, with conditional Pak4 gene 
deletion in the mammary gland and pancreas, are valuable tools to study the role of PAK4 in 
normal physiology and diseases affecting these two organs. We further utilized the mouse 
model introduced in paper II to study the role of Pak4 in Kras-induced PDAC development. 
Our results uncover a crucial role for PAK4 in PDAC development since Pak4 depletion in the 
Kras-induced PDAC mouse model causes senescence-like growth arrest in the preneoplastic 
lesions [Figure 8]. These data, together with our recent finding that PAK4 overexpression 
could abrogate oncogene-induced senescence (OIS) in the mammary epithelial cells, suggests 
PAK4 as an important mediator that both regulates further progression of preneoplastic lesions 
to cancer and overcomes the OIS barrier (216). Given that PAK4 is amplified and 
overexpressed in human PDAC (paper III), the work presented in this thesis suggest PAK4 
inhibition as a potential therapeutic strategy that could both restore preneoplastic lesions to 
their “un-differentiated” normal state and install a senescence-like growth arrest phenotype 
(219, 263). 
 
Figure 8: Schematic illustration model of the role of PAK4 in Acinar-to-Ductal reprogramming. 
Upon Kras oncogene insult, pancreatic acinar cells undergo acinar-to-ductal reprogramming (ADR). 










6 POINTS OF PERSPECTIVE 
Future research 
Many confounding factors need to be determined to fully evaluate the mechanism involved in 
the PAK4 regulation of ADR during PDAC progression.  
Both chronic and acute inflammation cooperate with oncogenic Kras to facilitate PDAC 
initiation and progression in humans (167, 181, 264, 265). Targeting inflammatory pathways 
in the context of PAK4 remained to be explored. This can be achieved in vivo by caerulein 
treatment, which induces excess secretion of pancreatic enzymes, and can induce either acute 
or chronic pancreatitis depending on the implemented dosage (266, 267).  
PDAC tumors are resistant to therapies, partly due to their desmoplastic stromal composition 
formed by the excess of fibroblasts and deposition of the ECM (268, 269). High desmoplastic 
composition is linked to more poorer patients’ survival. In vivo studies performed in KrasG12D 
mouse model (used in paper III) indicate that increased ECM stiffness is linked to epithelial 
to mesenchymal transition (EMT) and is associated with chemotherapy resistance (270). 
Therefore, it would be interesting to closely examine if there is any changes to the tumor 
microenvironment in terms of ECM stiffness, immune cells, and cancer-associated fibroblast 
composition upon Pak4 gene depletion in our mouse model.  
Clinical implications 
Because PAK4 expression is increased in pancreatic lesions and PDAC tumor tissues, targeting 
PAK4 might be an efficient way to delay the progression of neoplastic PanIN lesions to further 
progress to aggressive PDAC tumors. In a clinical setting, PAK4 was directly inhibited using 
inhibitors such as ATP-competitive compound (PF-3758309), which unfortunately failed to 
pass phase I trial due to its undesirable pharmacokinetic characteristics (271). However, in 
recent years, PAK4 allosteric modulators (KPT-9274, KPR-7523, and KPT-7189) were 
explored, and KPT-9274 was tested in the early clinical phases (272). Our results suggest a role 
for PAK4 in the initiation stages of PDAC; this is important since PAK4 inhibition can be used 








7 POPULAR SUMMARY OF THE THESIS 
 
“Cell migration” is a process in which cells not only walk around in the tissue they belonged 
to but can also start to invade their neighboring tissues. Migration of cells is crucial 
throughout the development of the fetus and ultimately the formation of the whole body, and 
it continues until adulthood. It is also the most important mechanism, which helps our body to 
heal a wound. There are many molecules that help fine-tuning this process. One of these 
molecules is PAK4.  
During my Ph.D. I tried to understand the role of PAK4 in the development of two organs, 
mammary gland (mouse milk gland), and pancreas. To do that, I worked with mice that lack 
the Pak4 gene in the mammary gland and pancreas (paper I &II). My results show that PAK4 
is not needed for the development of these two organs.  
Pancreatic cancer is an aggressive disease in which patients usually die in less than five years 
from the diagnosis. We know that PAK4 is expressed excessively in patients with pancreatic 
cancer. Therefore, I studied the role of Pak4 in the pancreatic cancer mouse model (paper III). 
I found out that mice lacking Pak4 in the pancreas, are less likely to develop cancer compared 




   ھمان نایاپ بلاطم هدیکچ
 ھب دنناوت یم ھکلب ،دننکیم تکرح دنتسھ نآ ھب قلعتم ھک یتفاب رد اھنت ھن اھلولس نآ رد ھک تسا یدنیآرف ،یلولس ترجاھم
 میمرتو ندب یاھمادنا لماکت ،نینج یریگ لکش رد ییازسب شقن یلولس تکرح .دننک ترجاھم زین دوخ ھیاسمھ یاھتفاب
 عقاو یلولس یاشغریز ھک دنتسھ ییاھلوکلومزا لکشتم یتکرح متسیس ھب زھجم تکرح یارب ام یاھلولس .دنکیم افیا مخز
 .PAK4 مان ھب تسینیئتورپ اھلوکلوم نیا زا یکی  .دنا هدش
 یسررب )هدعملازول( سارکناپو ھنیس مادنا ود یریگ لکشرد ار PAK4 شقن ھک مدرک یعس یرتکد نارود لوط رد نم
 تاقیقحت ھجیتن .دندوب سارکناپ و یریش ددغردPAK4  نژ دقاف ھک مدرک راک ییاھشوم اب نم ،راک نیا ماجنا یارب .منک
 .) ٢و١ ھلاقم رد جیاتن( دنکیمن داجیا یلکشم مادناود نیا یعیبط دشر یارب  PAK4 دوبن ھک تسا نیا هدنھدناشن نم
 یرامیب صیخشت زا دعب لاس جنپ زا رتمک رد نایالتبم بلغا ھک تساھ ناطرس نیرت میخدب زا یکی سارکناپ ناطرس
   .)٣ ھلاقم رد جیاتن( مدرک یسررب سارکناپ ناطرس تفرشیپ رد ار PAK4 شقن یرتکد زت ھمادا رد .دننکیم توف
 ھک ییاھشوم روطنیمھو دوشیم نایب رتشیب سارکناپ ناطرس نارامیب رد PAK4 ھک تسا نیا هدنھد ناشن متاقیقحت ھجیتن
   .دنراد ار یرت ھتسھآ ناطرس تفرشیپ ریس دننکیمن نایب ار نژ نیا
 زا یکی ناونع ھب  PAK4 نیئتورپ ندرک دودحم زا ناوتب هدنیآرد ،نم تاقیقحت ھجیتن نتفرگ رظن رد اب ھک تسا دیما
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